Dr. Tatjana Kolevska, MD
Claim this profileKaiser Permanente-Vallejo
Area of expertise
Cancer
Tatjana Kolevska, MD has run 5 trials for Cancer. Some of their research focus areas include:
Cutaneous Melanoma
Tatjana Kolevska, MD has run 5 trials for Cutaneous Melanoma. Some of their research focus areas include:
Affiliated Hospitals
Kaiser Permanente-Vallejo
Kaiser Permanente-Santa Teresa-San Jose
Clinical Trials Tatjana Kolevska, MD is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) with or without nivolumab to the effect of modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) with or without nivolumab for the treatment of patients with advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, or gastric adenocarcinoma. The usual approach for patients who are not in a study is treatment with FOLFOX with some receiving an immunotherapy drug, either nivolumab or pembrolizumab, in addition to FOLFOX chemotherapy. The usual approach is defined as care most people get for cancer in the stomach, esophagus, or gastroesophageal junction. Fluorouracil is in a class of medications called antimetabolites. It stops cells from making DNA and may kill tumor cells. Leucovorin in a class of medications called folic acid analogs. When used with fluorouracil it enhances the effects of this chemotherapy drug. Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It blocks a certain enzyme needed for cell division and DNA repair, and may kill cancer cells. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill cancer cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Some patients on this trial will receive nivolumab, in addition to mFOLFOX or mFOLFIRINOX chemotherapy. mFOLFIRINOX with or without nivolumab may be more effective than mFOLFOX with or without nivolumab by shrinking the tumor in patients with advanced, unresectable, or metastatic HER2-negative esophageal, gastroesophageal junction, or gastric adenocarcinoma.
Recruiting
2 awards
Phase 3
2 criteria
Multiple Targeted Therapies
for Meningioma
This trial studies four drugs to treat patients with worsening meningioma. These drugs work by blocking enzymes that the tumor cells need to grow. The trial focuses on patients whose tumors have specific genetic mutations.
Recruiting
1 award
Phase 2
10 criteria
More about Tatjana Kolevska, MD
Clinical Trial Related
3 years of experience running clinical trials · Led 22 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Tatjana Kolevska, MD has experience with
- Nivolumab
- Ipilimumab
- Pembrolizumab
- Lenalidomide
- MFOLFIRINOX
- Carboplatin
Breakdown of trials Tatjana Kolevska, MD has run
Cancer
Cutaneous Melanoma
Melanoma
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tatjana Kolevska, MD specialize in?
Tatjana Kolevska, MD focuses on Cancer and Cutaneous Melanoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage II.
Is Tatjana Kolevska, MD currently recruiting for clinical trials?
Yes, Tatjana Kolevska, MD is currently recruiting for 5 clinical trials in Vallejo California. If you're interested in participating, you should apply.
Are there any treatments that Tatjana Kolevska, MD has studied deeply?
Yes, Tatjana Kolevska, MD has studied treatments such as Nivolumab, Ipilimumab, Pembrolizumab.
What is the best way to schedule an appointment with Tatjana Kolevska, MD?
Apply for one of the trials that Tatjana Kolevska, MD is conducting.
What is the office address of Tatjana Kolevska, MD?
The office of Tatjana Kolevska, MD is located at: Kaiser Permanente-Vallejo, Vallejo, California 94589 United States. This is the address for their practice at the Kaiser Permanente-Vallejo.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.